Paper Details

  1. Home
  2. Paper Details

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine vaccines in India.

Author: AmdekarYeshwant K, BalasubramanianS, BavdekarAshish, BhatSwarna Rekha, ChhatwalJugesh, EminiEmilio A, GadgilDurga, GruberWilliam C, JiangQin, LalwaniSanjay K, PrideMichael, ScottDaniel A, TanseySusan P, VergheseValsan Philip

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Streptococcus pneumoniae infections are a significant health problem in children, especially in India. This study compares the effectiveness and safety of two pneumococcal vaccines: 13-valent pneumococcal conjugate vaccine (PCV13) and 7-valent pneumococcal conjugate vaccine (PCV7). The study is being conducted at 12 sites in India.
Paper Details　
Original Abstract of the Article :
The childhood burden of disease attributable to Streptococcus pneumoniae is particularly high in India. The immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) were compared with 7-valent pneumococcal conjugate vaccine (PCV7) in a randomized, active-controlled, double-blind...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1097/INF.0b013e31827b478d

データ提供：米国国立医学図書館（NLM）

Pneumococcal Vaccine in India: A Quest for Protection in a Challenging Terrain

The desert of childhood diseases in India is a vast and unforgiving landscape, with pneumococcal infections posing a significant threat to young lives. This study investigates the immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) in healthy infants and toddlers in India. The study compared PCV13 to a 7-valent pneumococcal conjugate vaccine (PCV7) in a randomized, controlled trial involving 12 sites across India. The researchers found that PCV13 provided strong immune responses against the targeted pneumococcal serotypes and was well-tolerated, offering hope for reducing the burden of pneumococcal disease in India. This study underscores the importance of vaccine research and development in addressing the unique challenges of childhood diseases in different parts of the world.

Pneumococcal Vaccine: A Beacon of Hope in the Desert

This study provides valuable data on the immunogenicity and safety of PCV13 in Indian infants and toddlers. The findings suggest that PCV13 offers a promising strategy for reducing the burden of pneumococcal disease in this region. The study's success highlights the crucial role of vaccine research and development in addressing the specific needs of different populations. It's like discovering a well-stocked oasis in the desert, offering a vital source of protection against disease.

Protecting Children in India: A Collaborative Journey Through the Desert

This study emphasizes the importance of international collaboration in addressing the global challenges of childhood diseases. The findings highlight the need for tailored vaccine strategies that cater to the specific needs of different populations. It's like embarking on a journey through a desert, with individuals from different regions working together to overcome the obstacles and find solutions that benefit everyone.

Dr. Camel's Conclusion

This study provides a ray of hope for reducing the burden of pneumococcal disease in India. The findings suggest that PCV13 is both immunogenic and safe in Indian infants and toddlers, offering a valuable tool for protecting young lives. It's like finding a hidden oasis in the desert, offering a much-needed source of protection and hope for a healthier future.

Date :
  1. Date Completed 2014-05-08
  2. Date Revised 2016-12-30
Further Info :

Pubmed ID

23190777

DOI: Digital Object Identifier

10.1097/INF.0b013e31827b478d

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.